Propanc Biopharma Changes Ticker Symbol

Propanc Biopharma (OTCQB:PPCB) announced it has changed the company’s ticker symbol from PPCH to PPCB.
As quoted in the press release:

“We wanted to highlight the Company’s recent milestones as our lead product, PRP, progresses towards First-In-Human studies, so the changes to our Company name and ticker symbol more accurately reflect our stage of growth,” said James Nathanielsz, Propanc Biopharma’s Chief Executive Officer. “Right now, we’re working hard with our R&D partners, like Q Biologicals and Technical University of Munich, who are assisting with the development of the GMP-compliant investigational medicinal product (IMP) manufacture of PRP for human use, so that we can prepare for our first clinical trial application in the UK.”
PRP is a solution for once daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen. Currently progressing towards First-In-Human studies, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 Billion by 2020. The Company’s initial target patient populations are pancreatic, ovarian and colorectal cancers, representing a combined market segment of $14 Billion predicted in 2020, by GBI Research.

Click here to read the full press release.